- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04095169
Biomarkers in Early-stage Spondyloarthritis
Axial spondyloarthritis (axSpA) is a group of inflammatory rheumatic conditions with inflammatory back pain caused by inflammation in the sacroiliac joints (SIJ) and back as hallmark.
Currently, no laboratory test or biomarker is cable of differentiating between patients with early-stage axSpA and persisting low back pain of other causes.
The objective of this study is to investigate the predictive value of baseline levels of the biomarkers Complement C3d and high-sensitive C-reactive protein (HsCRP) identifying bone marrow oedema (BME) at MRI of the SIJ at baseline.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, no laboratory test or biomarker is cable of differentiating between patients with early-stage axSpA and persisting low back pain of other causes. Human leukocyte antigen (HLA) B27 is not an acute biomarker, but a prognostic marker for the development of axSpA.
C-reactive protein (CRP) is commonly used as an acute biomarker in different inflammatory conditions. Previous studies have shown that only 40-60% of ankylosing spondylitis (AS) patients with clinical signs of active disease have elevated levels of CRP.
Earlier studies regarding the complement C3 split product C3d have shown a correlation between inflammatory diseases like AS and elevation of C3d. Those studies were based on a small number of cases, but a newer study from 2016 has shown a correlation between different biomarkers, including C3 and new fatty lesions at MRI in Golimumab treated AS patients.
Objective To investigate the predictive value of baseline levels of C3d and hsCRP identifying bone marrow oedema (BME) at MRI of the sacroiliac joints (SIJ) at baseline.
Design:
The study is a prospective cohort study including patients, aged 18-45 years, having unspecific low back pain registered in the Spines of Southern Denmark (SSD) cohort including patients referred to the Spine Centre of Southern Denmark.
At baseline, all patients filled in a standardised questionnaire and were interviewed identifying inflammatory symptoms followed by a clinical examination focusing on symptoms related to the SIJ. Blood samples were taken and analysed for HLA-B27 (prognostic biomarker). Furthermore, all patients underwent an MRI of the spine including the SIJ.
In total, 1037 patients were included, 696 had blood tests taken and gave consent for further use for research purposes.
For research purposes, the blood samples were stored in the Molecular Biology of Infectious Agents in the Early Diagnosis of Spondyloarthritis biobank (MICSA). The biobank is hosted by the research group at Graasten Rheumatological Hospital. Of the 696 patients who gave consent,188 patients were examined by a Rheumatologist at baseline. Of those 96 patients fulfilled the criteria of having axSpA according to The Assessment of SpondyloArthritis international Society (ASAS) criteria, 38 patients had inflammatory changes at MRI or had one feature consisting with spondyloarthritis, but did not fulfil the ASAS criteria. 82 randomly selected patients with low back pain were included as a control group.
In total, 216 patients were defined as the cohort included for further analysis in this study.
Data:
The Department of Clinical Biochemistry at Vejle Hospital has previously assisted in the collection and storage of MICSA samples. It is technically possible to use the stored frozen MICSA samples for analysing C3d.
In total, 184 (of 216) baseline samples were accessible for further analysis. The baseline samples will be analysed for C3d with the use of EDTA (ethylenediaminetetraacetic acid) plasma and treated according to the local protocol for such analyses.
MRI
All patients in the MICSA cohort have had an MRI of the spine including the SIJ at baseline. Two experienced radiologists have systematically described the MRI regarding signs of inflammatory changes including BME.
Statistics:
STATA (version 15.0) will be used for statistical analysis. Parametric data will be reported as the mean and standard derivation (SD) or One-way analysis of variance (ANOVA). In between-group comparisons for continuous and categorical demographic variables will be performed with the independent sample t-test and Pearson Chi-square test or Fisher´s exact test. The Kruskal-Wallis test and interquartile range will be used to describe nonparametric data. Logistic regression analysis will be used to test independent variables as predictive factors for BME detected by MRI, resulting in odds-ratios, sensitivity, specificity, and area under the curve (AUC). This will be followed by multivariate logistic regression to evaluate the potential effect of other variables. A p-value < 0.05 is considered statistically significant.
Sample size and power calculation:
A previous study with patients suspected of having spondyloarthritis has found a significant difference in mean levels of C3 between groups with 23 and 22 participants, respectively.
By the use of means and SD from the above study and alfa= 0.05, beta= 0.2, power 0.8 and enrollment ratio 1:2 the sample size in our study is calculated to n:10 and n:20 respectively.
It is therefore expected, that a significant difference in C3d levels between the three groups in the present study can be detected based on the size of each group in the MISCA cohort.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- patients from the Spines of Southern Denmark cohort who underwent MRI, blood samples, and clinical examination by a rheumatologist.
- aged 18-45
- three months of low back pain prior to inclusion
Exclusion criteria:
- < 3 months of low back pain
- not wish to participate/ did not sign consent form
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
axSpA
Patients with low back pain ≥three months who a) fulfilled the ASAS definition for a positive MRI scan of sacroiliac joints (definite inflammation) or b) were HLA-B27 positive with at least one concomitant clinical spondyloarthritis feature.
|
Evaluation of C3d levels in EDTA samples from participants
|
non-axSpA
Patients with a) positive MRI according to the ASAS definition, but no additional clinical spondyloarthritis features, or b) positive HLA-B27 and one clinical spondyloarthritis feature.
|
Evaluation of C3d levels in EDTA samples from participants
|
Controls
Patients with non-specific low back pain without spondyloarthritis-related features and negative MRI SIJ.
|
Evaluation of C3d levels in EDTA samples from participants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C3d levels
Time Frame: 1 month after sampling of C3d
|
Baseline levels of C3d between 3 groups
|
1 month after sampling of C3d
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI changes
Time Frame: 3 months after sampling of C3d
|
correlation between baseline C3d and inflammatory changes at MRI
|
3 months after sampling of C3d
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Allan Nygaard, MD, Spinecentre of Southern Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Bone Diseases, Infectious
- Ankylosis
- Spondylitis
- Spondylarthritis
- Spondylitis, Ankylosing
- Physiological Effects of Drugs
- Immunologic Factors
- Complement System Proteins
- Complement C3
- Complement C3d
Other Study ID Numbers
- SpAbio
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankylosing Spondylitis
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHRecruitingActive Ankylosing SpondylitisChina
-
AbbVieBoehringer IngelheimCompletedAnkylosing Spondylitis (AS)
-
Sun Yat-sen UniversityUnknownEarly Ankylosing Spondylitis
-
AbbVieCompletedAnkylosing Spondylitis (AS)United States, Australia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, United Kingdom
-
Tongji HospitalWuhan Central Hospital; Wuhan Hospital of Traditional Chinese MedicineRecruitingAnkylosing Spondylitis (AS)China
-
Chinese University of Hong KongCompletedAnkylosing Spondylitis(AS)China
-
AbbVieCompletedAnkylosing Spondylitis (AS)Taiwan
-
Tianjin Hemay Pharmaceutical Co., LtdCompletedActive Ankylosing SpondylitisChina
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingActive Ankylosing SpondylitisChina
-
Assiut UniversityUnknownActive Sacroiliitis in Ankylosing Spondylitis
Clinical Trials on Complement C3d test (blood sample)
-
Sohag UniversityNot yet recruitingPesticide Adverse ReactionEgypt
-
Medical University of WarsawCompletedFemoral Neck Fractures | Bone Loss | Bone Resorption | Muscle Loss | Muscle Damage | Pertrochanteric FracturePoland
-
Caroline Nørgaard-PedersenDepartment of Clinical Immunology, Odense University Hospital, DK; Department...RecruitingRecurrent Pregnancy Loss, Not PregnantDenmark
-
Hospices Civils de LyonCompleted
-
European Georges Pompidou HospitalInstitut National de la Santé Et de la Recherche Médicale, France; ONIRISCompletedBreast Cancer | Lymph Node Metastases | Persistant Organic Pollutants
-
Children's National Research InstituteEmory University; University of Texas Southwestern Medical Center; Arizona State...Completed
-
University Hospital, Strasbourg, FranceCompletedSARS-CoV-2 Serological Status | SARS-CoV-2 SeroprevalenceFrance
-
Centre Hospitalier Universitaire de NīmesInstitut Bergonié; Institut de cancérologie Strasbourg Europe; Centre Antoine... and other collaboratorsRecruiting
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceActive, not recruiting
-
University Hospital Hradec KraloveAmerican Association for Thoracic SurgeryRecruitingInfections | Systemic Inflammatory Response Syndrome | Immunological Abnormality | Aortic Diseases | Thoracic Aortic AneurysmCzechia